3000 PEGASUS PARK DRIVE, DALLAS, TX
Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News, Articles of Incorporation
Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Amended material disclosure
Investor Presentation
Q2
Q1
FY 2023
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership